George Naumov, PhD.

Dr. George Naumov is the COO and Head of Business Development at RS Oncology LLC. Prior to his current position Dr. Naumov was the Head of Clinical Science at Karyopharm Therapeutics Inc, Newton MA. He was involved with the development and approval of XPOVIO (Selinexor), a first in class SINE XPO1 antagonist, in relapsed multiple myeloma. Dr. Naumov was involved with the development and approval of Zejula (Niraparib), the first and only once-daily PARP inhibitor to be clinically active independent of a biomarker, in patients with ovarian cancer while at TESARO (acquired byGSK). Previously, Dr. Naumov was a management consultant with the DavCard Group and MedPharma Partners. Dr. Naumov has over 20 years of consulting experience working with life sciences startups and pharma/biotech companies. He was a cofounder, President & CEO of Zateras Therapeutics Inc., a Boston based startup developing immune modulating therapeutics for treatment of cancer, sepsis, and autoimmune diseases. Dr. Naumov served as a Chair of the life sciences screening committee for Boston Harbor Angels and a member of Investors Collaborative. Previously he was a Sr. Research Biologist in Oncology at Merck & Co. He was a scout for Merck Venture Fund and served as an Oncology franchise representative on the “Novel technologies in licensing committee”.

He holds a B.Sci. (Hon.) in biochemistry from Queen’s University at Kingston and a Ph.D. in Medical Biophysics from the University of Western Ontario, Canada. He ran a laboratory under Dr. Judah Folkman at Harvard Medical School and Children’s Hospital Boston. He is widely published in the field of oncology. During his career, Dr. Naumov has built a scientific and business brand of collaboration and innovation, both in academic and commercial settings